#1 Clinical Trials Search in Europe

Systemic candida – Diagnostics

Go back

Systemic candidiasis, also known as invasive candidiasis, is a serious fungal infection that requires prompt and accurate diagnosis. Understanding how doctors identify and test for this condition is essential for anyone at risk, particularly those in hospital settings or with weakened immune systems.

Introduction: Who Should Undergo Diagnostics

Systemic candidiasis is not a condition that affects healthy people going about their daily lives. This severe infection occurs when a type of yeast called Candida, which normally lives harmlessly in small amounts on our skin and inside our bodies, grows out of control and spreads to internal organs. The infection primarily affects people who are already ill or hospitalized, making it challenging to determine who needs testing and when.[1]

Diagnostics for systemic candidiasis should be considered for hospitalized patients who develop fever and chills that do not respond to antibiotics. This is particularly important if they have risk factors that make them vulnerable to this type of infection. Since most people who develop invasive candidiasis are already sick from other conditions, it can be very difficult to tell which symptoms come from their original illness and which might signal a Candida infection spreading through their body.[1]

Certain groups of people have a much higher chance of developing systemic candidiasis and should be monitored more closely. These include babies born prematurely, people who need to be fed through a tube, individuals with weakened immune systems, and those who have recently undergone major surgery. Anyone with a central venous catheter (a tube inserted into a large vein to deliver medication or nutrition) faces increased risk, as Candida can travel along these medical devices into the bloodstream.[1]

People taking broad-spectrum antibiotics for extended periods should also be watched carefully. These powerful medications can kill off the good bacteria that normally keep Candida in check, allowing the yeast to multiply unchecked. Similarly, patients receiving chemotherapy, those who have had organ transplants, or individuals with diabetes may need diagnostic testing if they develop unexplained fever while in the hospital.[2]

⚠️ Important
If you or a loved one is hospitalized and develops a fever that does not improve with antibiotics, ask the healthcare team whether testing for fungal infections might be appropriate. Early diagnosis can be life-saving, as systemic candidiasis can lead to organ failure and death without prompt treatment.

Diagnostic Methods for Identifying Systemic Candidiasis

Diagnosing systemic candidiasis presents significant challenges for medical professionals. The symptoms often overlap with bacterial infections and other conditions, making it difficult to pinpoint the exact cause of illness. However, several diagnostic methods are available to help identify this dangerous fungal infection.

Blood Cultures

The most common and traditional method for diagnosing systemic candidiasis is through blood cultures. In this test, healthcare providers draw blood samples from the patient and send them to a laboratory where they are placed in special containers that encourage any microorganisms present to grow. If Candida yeast is in the bloodstream, it will multiply in these containers over several days, allowing laboratory technicians to identify it.[7]

However, blood cultures have a significant limitation. Studies show they are only 70% to 80% sensitive in detecting invasive candidiasis. This means that even when someone has the infection, blood cultures may fail to detect it in 20% to 30% of cases. In autopsy studies where systemic candidiasis was confirmed after death, blood cultures had only identified the infection in 21% to 71% of patients while they were still alive. This gap highlights why doctors cannot rely on blood cultures alone.[2][14]

Beta-D-Glucan Testing

Because blood cultures can miss infections, doctors have turned to newer diagnostic tools. One important test measures beta-D-glucan, a substance found in the cell walls of many fungi, including Candida. When fungal cells break down in the body, they release beta-D-glucan into the bloodstream, where it can be detected through a blood test.[2]

The beta-D-glucan test works as an adjunctive or supporting diagnostic tool rather than a definitive test on its own. This is because beta-D-glucan can be released by various types of fungi, not just Candida, so a positive result does not specifically confirm Candida infection. However, research shows that when beta-D-glucan testing is combined with another marker called procalcitonin, the combination can help rule out invasive candidiasis with very high sensitivity (98%) and a strong negative predictive value (95%). In simpler terms, if both tests are negative, doctors can be quite confident the patient does not have systemic candidiasis.[14]

T2 Magnetic Resonance Assay

A more advanced diagnostic tool is the T2 magnetic resonance assay, also called T2Candida. This technology uses magnetic resonance principles to detect Candida DNA directly in blood samples. The advantage of this test is that it can identify specific Candida species much faster than traditional blood cultures, providing results within hours rather than days. This speed can be crucial when every hour matters in treating a life-threatening infection.[2][14]

MALDI-TOF Mass Spectrometry

Once Candida has been detected through blood cultures or other methods, laboratories can use MALDI-TOF mass spectrometry to quickly identify which specific species of Candida is causing the infection. This matters because different Candida species respond differently to antifungal medications. Some species are naturally resistant to certain drugs, so knowing exactly which species is present helps doctors choose the most effective treatment.[2]

Additional Laboratory Tests

When systemic candidiasis is suspected, doctors typically order a comprehensive panel of blood tests beyond those specifically looking for the fungus. These include a full blood count (FBC) to check white blood cell levels, blood gas analysis to measure oxygen and acid levels, lactate levels to assess tissue damage, kidney and liver function tests, and glucose measurements. These tests help doctors understand how severely the infection is affecting the body’s organs and systems.[2]

Imaging Studies

When doctors suspect that Candida has spread to specific organs, they may order imaging tests. Ultrasound, CT scans, or MRI scans can reveal abscesses or other abnormalities in organs like the liver, spleen, kidneys, or brain that might indicate fungal infection. In some cases, a specialized imaging test called 18F-FDG PET/CT can help identify sites of infection throughout the body.[2]

Tissue Biopsies

Sometimes the only way to confirm systemic candidiasis in a particular organ is to take a small sample of tissue through a procedure called a biopsy. Laboratory specialists can then examine the tissue under a microscope and perform tests to determine whether Candida is present. This is particularly helpful when the infection affects organs other than the blood, such as the heart valves, bones, or brain lining.[2]

Eye Examinations

Healthcare providers generally recommend that all patients diagnosed with candidemia undergo an ophthalmological examination. This eye exam checks for endophthalmitis, a serious infection inside the eye that can occur when Candida spreads through the bloodstream. Patients with eye involvement may experience blurred vision, sensitivity to light, or vision changes. Detecting and treating this complication early is essential to prevent permanent vision damage.[2][9]

⚠️ Important
There is currently a clear deficiency in approved, highly sensitive, and precise diagnostic techniques for systemic candidiasis. Because no single test is perfect, doctors often use a combination of different diagnostic methods to confirm the infection and guide treatment decisions.

Diagnostics for Clinical Trial Qualification

When patients with systemic candidiasis are considered for enrollment in clinical trials testing new treatments, specific diagnostic criteria must be met. Clinical trials require rigorous documentation to ensure that participants truly have the condition being studied and to maintain the quality and reliability of research results.

For most clinical trials involving invasive candidiasis, blood culture confirmation is typically required as the gold standard for enrollment. This means that patients must have positive blood cultures showing Candida growth before they can participate. Trials may specify that cultures must be positive within a certain timeframe, such as within 24 to 48 hours before enrollment, to ensure that participants have active infections requiring immediate treatment.[10]

Clinical trials also commonly require identification of the specific Candida species causing the infection. As mentioned earlier, MALDI-TOF mass spectrometry or other identification methods help determine whether the infection is caused by Candida albicans, Candida glabrata, Candida parapsilosis, or other species. Some trials may specifically include or exclude certain species based on the treatment being tested.[2]

Researchers conducting clinical trials often incorporate newer diagnostic technologies as secondary endpoints or for additional monitoring. For example, trials might measure beta-D-glucan levels or use T2Candida assays at regular intervals to track how well patients are responding to experimental treatments, even though these tests might not be required for initial enrollment.

Patient eligibility for clinical trials also depends on baseline health assessments. Comprehensive blood tests measuring kidney function, liver function, blood cell counts, and other parameters help researchers understand each participant’s overall health status. These baseline measurements are then compared to follow-up tests to determine whether the experimental treatment is working and whether it causes any harmful side effects.

Some trials studying treatments for invasive candidiasis may also require imaging studies at enrollment and during follow-up. CT scans or MRI scans at baseline can document the extent of organ involvement, and repeat imaging later shows whether the infection is clearing up or spreading despite treatment. These objective measures provide valuable data about treatment effectiveness.

Clinical trials must also carefully document any risk factors that made participants vulnerable to systemic candidiasis in the first place. Information about central venous catheters, recent surgeries, antibiotic use, immunosuppressive medications, and underlying health conditions helps researchers understand which patient populations might benefit most from new treatments being tested.

Prognosis and Survival Rate

Prognosis

The outlook for patients with systemic candidiasis varies considerably depending on several important factors. The condition can be life-threatening, and without immediate treatment, it can lead to organ failure and death. Patients who are already severely ill from other conditions, those with weakened immune systems, and those experiencing delays in diagnosis and treatment generally face poorer outcomes.[1]

Starting antifungal treatment within 24 hours of diagnosis significantly improves patient outcomes. The specific Candida species causing the infection also influences prognosis, as some species are more resistant to commonly used antifungal medications than others. An important part of treatment involves removing the source of infection whenever possible, such as taking out contaminated central venous catheters or draining abscesses, which greatly improves the chances of recovery.[2]

The location where Candida has spread within the body also affects prognosis. Candidemia, where the infection remains primarily in the bloodstream, may have a better outcome than cases where the fungus has infected the heart valves (endocarditis), the protective layers around the brain and spinal cord (meningitis), or multiple internal organs simultaneously. Patients who develop complications such as eye infections or widespread organ damage face more challenging recoveries.[1]

Survival rate

While specific survival statistics vary across different studies and patient populations, systemic candidiasis is associated with high mortality rates. The infection is recognized as one of the most common healthcare-associated infections in the United States and carries significant risk of death, particularly among critically ill patients. Studies examining treatment outcomes in clinical trials suggest that the choice of antifungal medication, specifically the use of echinocandin drugs, may improve survival rates compared to other treatment options.[10]

The emergence of drug-resistant Candida species, particularly Candida auris, has raised concerns about future survival rates. This species can be resistant to multiple antifungal medications and is associated with high mortality. Patients infected with multidrug-resistant strains face limited treatment options and potentially worse outcomes than those with infections caused by susceptible Candida species.[8]

Ongoing Clinical Trials on Systemic candida

References

https://my.clevelandclinic.org/health/diseases/22308-invasive-candidiasis

https://bestpractice.bmj.com/topics/en-us/1062

https://www.ncbi.nlm.nih.gov/books/NBK560624/

https://www.cdc.gov/candidiasis/about/index.html

https://my.clevelandclinic.org/health/diseases/23198-candidiasis

https://www.cedars-sinai.org/health-library/diseases-and-conditions/c/candida-infection-thrush.html

https://www.cdc.gov/candidiasis/hcp/clinical-overview/index.html

https://en.wikipedia.org/wiki/Invasive_candidiasis

https://my.clevelandclinic.org/health/diseases/22308-invasive-candidiasis

https://emedicine.medscape.com/article/213853-treatment

https://www.cdc.gov/candidiasis/treatment/index.html

https://www.ncbi.nlm.nih.gov/books/NBK560624/

https://www.idsociety.org/practice-guideline/candidiasis/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9219674/

https://bestpractice.bmj.com/topics/en-us/1062

https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/candida-cleanse/faq-20058174

https://www.healthline.com/nutrition/candida-symptoms-treatment

https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/candida-cleanse/faq-20058174

https://my.clevelandclinic.org/health/diseases/22308-invasive-candidiasis

https://www.rupahealth.com/post/a-functional-medicine-candida-overgrowth-protocol

https://pmc.ncbi.nlm.nih.gov/articles/PMC10302699/

https://www.cdc.gov/candidiasis/prevention/index.html

https://advancedfunctionalmedicine.com.au/combatting-candida-overgrowth/

https://www.amymyersmd.com/blogs/articles/solution-candida-med-school

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

More information about
Systemic candida:

FAQ

How do doctors test for systemic candidiasis?

Doctors primarily use blood cultures to test for systemic candidiasis by drawing blood samples that are grown in laboratory containers for several days. If Candida is present, it will multiply and become visible. They may also use newer tests like beta-D-glucan assays, T2 magnetic resonance assays, and MALDI-TOF mass spectrometry to identify the infection more quickly and determine which Candida species is causing it.[2][7]

Can systemic candidiasis be diagnosed without blood tests?

While blood tests are the primary diagnostic method, systemic candidiasis can sometimes be diagnosed through tissue biopsies if the infection has spread to specific organs. Imaging studies like CT scans or MRI can reveal signs of infection in organs, but these must be confirmed through laboratory testing. Blood cultures or other blood-based tests remain the standard for diagnosing candidemia, the most common form of systemic candidiasis.[2]

Why do blood cultures sometimes fail to detect systemic candidiasis?

Blood cultures are only 70% to 80% sensitive, meaning they miss the infection in 20% to 30% of cases. This can happen because Candida may be present in low numbers in the bloodstream at the time blood is drawn, or the infection may be primarily located in organs rather than circulating freely in blood. In autopsy studies of people who had systemic candidiasis, blood cultures had only detected the infection in 21% to 71% of patients before death.[2][14]

What is the beta-D-glucan test and how does it help diagnose candidiasis?

Beta-D-glucan is a substance found in the cell walls of many fungi, including Candida. When fungal cells break down in the body, they release beta-D-glucan into the bloodstream where it can be measured through a blood test. While this test does not specifically identify Candida (since other fungi also produce beta-D-glucan), when combined with another marker called procalcitonin, it can help exclude invasive candidiasis with 98% sensitivity and 95% negative predictive value.[2][14]

Do I need an eye exam if I’m diagnosed with systemic candidiasis?

Yes, healthcare providers generally recommend that all patients with candidemia (Candida in the bloodstream) undergo an ophthalmological examination. This is because the infection can spread to the eyes and cause a serious condition called endophthalmitis, which may lead to permanent vision damage. The eye exam helps detect this complication early, even before you notice symptoms like blurred vision or light sensitivity.[2][9]

🎯 Key takeaways

  • • Systemic candidiasis primarily affects hospitalized patients who are already ill, particularly those with central venous catheters, weakened immune systems, or taking broad-spectrum antibiotics.
  • • Blood cultures remain the primary diagnostic tool, but they miss the infection in up to 30% of cases, requiring doctors to use multiple testing methods.
  • • Newer diagnostic technologies like beta-D-glucan testing and T2 magnetic resonance assays provide faster results and can help rule out infection when negative.
  • • Identifying the specific Candida species through MALDI-TOF mass spectrometry is crucial because different species respond differently to antifungal medications.
  • • All patients with candidemia should receive an eye examination to check for spread of infection that could cause permanent vision loss.
  • • Starting treatment within 24 hours of diagnosis significantly improves survival rates, making prompt and accurate diagnosis critically important.
  • • Clinical trials require confirmed blood culture results and species identification as standard enrollment criteria to ensure participants truly have invasive candidiasis.
  • • There is currently no perfect diagnostic test for systemic candidiasis, and doctors must use a combination of methods to confirm the infection and guide treatment.

Connected medications: